- The Scientific Advisory Board brings together distinguished experts in oncology, immunology, and CAR T-cell therapy to support CARGO’s cell therapy development programs, novel platform technologies, and future manufacturing strategy - SAN MATEO, Calif., Dec.
SAN MATEO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO”), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the pricing of its initial public offering of 18,750,000
— Accomplished clinical leader with significant expertise in hematology/oncology drug development and a track record of advancing multiple modalities of cancer therapeutics — SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development – SAN MATEO, Calif., September 12, 2023 – CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance
– Board of Director appointments follow the Company’s recent launch and $200 million Series A financing in March 2023 – – Appointments include industry veterans John Orwin as Chairman, David Lubner as Independent Director and Strategic Finance and Audit Committee Chair, and Dr.
SAN MATEO, Calif., May 31, 2023 – CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m.
– Series A financing co-led by Third Rock Ventures, RTW and Perceptive Xontogeny Venture Fund, and includes new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, T. Rowe Price, Cormorant Asset Management and Piper Heartland with participation from existing seed